Lit Matters 1: The Experts Weigh In: IV Contrast in Patients with Kidney Disease

Modern IV iodinated contrast is safer in kidney disease than many clinicians were taught, and the biggest error is often delaying a needed contrast-enhanced CT. The key distinction is contrast-associated AKI versus true contrast-induced AKI, with risk driven mainly by baseline eGFR rather than contrast fear alone.

IV Contrast in Kidney Disease

• CA-AKI versus CI-AKI: AKI within 48 hours of contrast is contrast-associated AKI, not proof of causation; that distinction explains why older contrast-nephropathy risk estimates likely overstated harm.
• Risk driven by eGFR: Baseline kidney function is the main signal, with CA-AKI rising stepwise as eGFR falls and the clearest concern concentrated in patients below 30 mL/min/1.73 m2.
• Low versus iso-osmolality contrast: Current evidence shows no confirmed clinically meaningful kidney-safety advantage of iso-osmolality over low-osmolality IV iodinated contrast for CT.
• Prophylaxis with IV fluids: Preventive treatment, when indicated, is IV volume expansion rather than N-acetylcysteine, and the patients most worth targeting are those with severe CKD who are not volume overloaded. We get into the practical caveats in the episode.
• Contrast as relative contraindication: Stage 4-5 CKD without maintenance dialysis is not an automatic reason to withhold contrast; if the scan answers a life-threatening question, contrast remains a relative rather than absolute contraindication.
• Single kidney and dose reduction: A solitary kidney does not add risk beyond the patient’s overall eGFR, and there is no evidence that empirically lowering contrast dose improves renal safety.